MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia (ALL) Intervention: Drug: Nilotinib Sponsor: Novartis Pharmaceuticals Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials
